0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Trimebutine maleate, a noncompetitive spasmolytic agent with some affinity for peripheral μ- and κ-opioid receptors has been evaluated as a treatment in a limited number of patients undergoing sedation-free full colonoscopy. The efficiency of such treatment was comparable to sedation-based colonoscopies to relieve from pain and discomfort.

          Related collections

          Author and article information

          Journal
          Eur J Pain
          European journal of pain (London, England)
          Wiley
          1532-2149
          1090-3801
          May 2016
          : 20
          : 5
          Affiliations
          [1 ] INSERM U1043, Toulouse, France.
          [2 ] CNRS U5282, Toulouse, France.
          [3 ] Centre de Physiopathologie de Toulouse Purpan (CPTP), Université de Toulouse, Université Paul Sabatier, France.
          [4 ] GIcare pharma Inc, Montréal, Canada.
          [5 ] Department of Physiology and Pharmacology, University of Calgary, Canada.
          Article
          10.1002/ejp.798
          26541237
          22d26102-772f-4df0-b5fc-bab2ca8621d2
          © 2015 European Pain Federation - EFIC®
          History

          Comments

          Comment on this article